NUVL - Nuvalent, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
NUVL price evolution
NUVL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1179.67 | $666.26 | $699.49 | $726.49 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1188.86 | $675.23 | $708.47 | $732.38 |
| Current liabilities | ||||
| Accounts payable | $15.93 | $7.4 | $13.4 | $9.27 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $51.13 | $38.19 | $33.43 | $31.82 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $67.73 | $38.19 | $33.43 | $31.82 |
| Shareholders' equity | ||||
| Retained earnings | -$472.29 | -$387.94 | -$330.78 | -$286.3 |
| Other shareholder equity | $1.37 | -$1.57 | -$1.32 | $0.03 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $726.49 | $477.99 | $290.63 | $10.65 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $732.38 | $482.46 | $293.82 | $10.65 |
| Current liabilities | ||||
| Accounts payable | $9.27 | $7.2 | $2.89 | $1.25 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $31.82 | $19.48 | $8.79 | $4.38 |
| Long term debt | $2.23 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $31.82 | $19.48 | $8.79 | $6.62 |
| Shareholders' equity | ||||
| Retained earnings | -$286.3 | -$160.08 | -$78.22 | -$31.89 |
| Other shareholder equity | $0.03 | -$0.49 | -$0.23 | -$0.28 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $76.33 | $65.15 | $52.59 | $46.44 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.04 | $0.17 | $0.38 | |
| Interest expense | $8.63 | $8.15 | $8.49 | $8.14 |
| Net income | ||||
| Net income | -$84.34 | -$57.17 | -$44.48 | -$38.29 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $149.49 | $86.11 | $45.82 | $16.91 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $23.27 | $4.25 | ||
| Net income | ||||
| Net income | -$126.22 | -$81.85 | -$46.34 | -$14.56 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$403.47 | -$190.56 | -$206.77 | -$143.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $560.39 | $10.12 | $5.99 | $336.85 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $33.86 | -$257.69 | -$236.87 | $93.58 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$143.53 | -$10.67 | -$220.03 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $336.85 | $248.92 | $318.22 | $22.27 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $93.58 | $173.28 | $58.19 | $7.32 |
News
Fundamentals
| Market cap | $7.18B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 70.93M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$224.28M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -32.01 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.16 |
|---|---|
| ROA | -27.15% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 23.07 |
| Quick ratio | N/A |